BROMODOMAIN AND EXTRA-TERMINAL (BET) PROTEIN INHIBITOR, INCB057643, IMPROVES BONE MARROW FUNCTION AND SHIFTS MEGAKARYOPOIESIS TO ERYTHROPOIESIS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS (MPNS)

EHA Library, Diana Alvarez Arias, 4160208

INTERNATIONAL MULTICENTRE EVALUATION OF ARTIFICIAL INTELLIGENCE (AI) AUGMENTED FIBROSIS GRADING IN A REAL-WORLD, CLINICAL COHORT OF 1000 PATIENTS

EHA Library, Timothy Ebsworth, 4160211

DECIPHERING FIBROTIC NICHES IN MPN USING NICHESPHERE: A CELLULAR INTERACTION MAP OF BONE MARROW FIBROSIS

EHA Library, Hélène Gleitz, 4160213

CLONAL EVOLUTION DURING MPN TRANSFORMATION IS SHAPED BY A COMPLEX INTERPLAY BETWEEN MUTATION ACQUISITION, GENETIC INTERACTIONS, AND ALLELIC DOSAGE EVENTS

EHA Library, Noushin Farnoud, 4160214

THE DYNAMIC LANDSCAPE OF IMMUNE ENVIRONMENT FOR MM PATIENTS RECEIVING T CELL REDIRECTING THERAPIES

EHA Library, Jin Lu, 4160215

A NOVEL JAK2 INHIBITOR OB756 INHIBITS MEGAKARYOPOIESIS DIFFERENTIATION AND PROPLATELET BIOGENESIS VIA PI3K-AKT SIGNALING PATHWAY IN PATIENTS WITH PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Jian Huang, 4160216

DECIPHERING THE ENHANCER LANDSCAPE OF PTPN11-MUTANT JUVENILE MYELOMONOCYTIC LEUKEMIA

EHA Library, Noel Gómez-Molina, 4160217

CLONAL DYNAMICS AND COMPLEXITY OF HEMATOPOIETIC STEM CELLS CO-MUTATED IN CALR AND TP53 DURING THE TRANSFORMATION OF CLASSICAL MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Syrine BEL HAJ YAHIA, 4160218

MACROPHAGE POLARIZATION AND PHAGOCYTIC ACTIVITY IN PTPN11-MUTATED JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML): IMPLICATIONS FOR IMMUNE EVASION AND THERAPEUTIC TARGETING

EHA Library, Jun Wang, 4160219

TRANSCRIPTIONAL REPROGRAMMING OF SPLENIC ENDOTHELIAL CELLS IN MYELOFIBROSIS

EHA Library, Francesca Lazzaroni, 4160222

THE INFLAMMASOME NEGATIVELY MODULATES HEME OXYGENASE 1 CONTRIBUTING TO BONE MARROW FIBROSIS IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Jessica Ferrigno, 4160224

HYDROXYUREA DRIVES CLONAL SELECTION OF TP53 MUTATED CELLS IN MYELOPROLIFERATIVE NEOPLASMS (MPN)

EHA Library, Nabih Maslah, 4160225

DECODING THE SUCNR1/HIF-1α /TNF-α AXIS: HOW MONOCYTES FUEL MYELOFIBROSIS IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Jieyu Wang, 4160227

THE CLONAL ORIGIN AND EVOLUTION OF HIGH-RISK MULTISYSTEM HISTIOCYTOSIS IN ADULTS

EHA Library, Kudzai Nyamondo, 4160228

MECHANISMS OF FIBROCYTE INDUCTION IN LYMPHOID MALIGNANCIES: THE ROLE OF CCL22 AND TIMP-1 IN SECONDARY MYELOFIBROSIS

EHA Library, Noriaki Tachi, 4160231

TYK2 IS SPECIFICALLY ACTIVATED IN CALR-MUTANT MYELOPROLIFERATIVE NEOPLASMS AND JAK2 EXPRESSION DETERMINES ITS DRUGGABILITY

EHA Library, Nicolas Chatain, 4160232

CD44 CONTRIBUTES TO EXTRAMEDULLARY HEMATOPOIESIS IN MYELOFIBROSIS PATIENTS BY REGULATING THE INTERPLAY BETWEEN MONOCYTE AND HEMATOPOIETIC STEM AND PROGENITOR CELLS

EHA Library, Camilla Tombari, 4160233

SURVIVAL IMPACT AND KINETICS OF HEMOGLOBIN IMPROVEMENT WITH MOMELOTINIB IN PATIENTS WITH MYELOFIBROSIS AND MODERATE TO SEVERE ANEMIA: POST HOC ANALYSES OF SIMPLIFY-1 AND MOMENTUM

EHA Library, Francesca Palandri, 4160235

SAFETY PROFILE OF LONG-TERM EXPOSURE TO RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS, ANALYSIS FROM A REAL-WORLD DATA NETWORK

EHA Library, Alberto Blanco Sánchez, 4160236

FIBROSIS GRADE BEFORE AND ITS RESOLUTION AFTER TRANSPLANTATION HAS NO PREDICTIVE VALUE IN MYELOFIBROSIS

EHA Library, Nico Gagelmann, 4160238

FINAL RESULTS OF A PILOT STUDY OF ELOTUZUMAB IN PATIENTS WITH MYELOFIBROSIS

EHA Library, Prithviraj Bose, 4160240

PROTECTIVE EFFECT OF ACETYLSALICYLIC ACID AND INTERFERON ALPHA ON LIVE BIRTH RATE IN MYELOPROLIFERATIVE NEOPLASMS: A META-ANALYSIS BASED ON THE SYSTEMATIC REVIEW OF 1,697 PREGNANCIES.

EHA Library, Monia Marchetti, 4160241

SURVIVAL OUTCOMES IN ACCELERATED AND BLAST PHASE MPN: A REAL-WORLD ANALYSIS FROM THE UK MPN CLINICAL STUDY GROUP.

EHA Library, Alexandros Rampotas, 4160242

IMPACTMF, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF IMETELSTAT VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS RELAPSED OR REFRACTORY TO JANUS KINASE INHIBITORS

EHA Library, John Mascarenhas, 4160248

LYMPHOCYTE TO MONOCYTE RATIO MAY PREDICT TRANSFORMATION TO MYELOFIBROSIS FOR POLYCYTHEMIA VERA PATIENTS TREATED WITH RUXOLITINIB: EXPERIENCE FROM MAJIC-PV TRIAL

EHA Library, Andrea Duminuco, 4160249

PROGNOSTIC IMPLICATIONS OF RED BLOOD CELL DISTRIBUTION WIDTH-TO-ALBUMIN RATIO IN PATIENTS WITH MYELOFIBROSIS: INSIGHTS FROM A 10-YEAR RETROSPECTIVE AND MULTICENTER COHORT

EHA Library, Jian Huang, 4160250

A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL TO ADDRESS THE IMPACT OF TARGETED FLUDARABINE ON THE INCIDENCE OF VIRAL COMPLICATIONS AFTER αßTCR/CD19 DEPLETED ALLO-HCT

EHA Library, Moniek de Witte, 4160251

ALPHABETA T-CELL / CD19 GRAFT DEPLETED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN COMBINATION WITH POST-TRANSPLANT RUXOLITINIB FOR MYELOFIBROSIS

EHA Library, Anniek Stuut, 4160252

STUDY DESIGN AND DEMOGRAPHICS OF IMPRSSION, A PHASE 2 OPEN-LABEL CLINICAL TRIAL EVALUATING TMPRSS6 ANTISENSE INHIBITOR SAPABLURSEN, IN POLYCYTHEMIA VERA

EHA Library, Terrance Barrett, 4160254

SEX INFLUENCES MPN PHENOTYPE AND CLINICAL OUTCOMES: A REAL WORLD STUDY OF 1167 SUBJECTS FROM THE QUEBEC REGISTRY

EHA Library, Geneviève Huynh-Trudeau, 4160255

HEMATOLOGIC IMPROVEMENT EXPERIENCED BY PACRITINIB-TREATED PATIENTS WITH MYELOFIBROSIS IN REAL-WORLD CLINICAL SETTINGS

EHA Library, Michael Marrone, 4160256

RESULTS OF ALLOGENEIC STEM CELL TRANSPLANTATION IN ADVANCED MYELOFIBROSIS

EHA Library, Jong Hyuk Lee, 4160259

GECACITINIB THERAPY'S IMPACT ON SYMPTOM BURDEN IN THE ZGJAK016 STUDY

EHA Library, Yi Zhang, 4160260

THE PROGNOSTIC IMPACT OF CYTOGENETIC AND MOLECULAR TESTING IN SECONDARY MYELOFIBROSIS

EHA Library, Holly Pertile, 4160262

FACTORS INFLUENCING CHR AND MR ACHIEVEMENT AND MAINTENANCE IN POLYCYTHEMIA VERA PATIENTS WITH HYDROXYUREA RESISTANCE/INTOLERANCE TREATED WITH ROPEGINTERFERON ALFA-2B

EHA Library, Sung-Eun Lee, 4160264

RENAL FUNCTION MODERATES ASSOCIATIONS OF RED CELL MASS AND PLASMA VOLUME WITH THROMBOTIC RISK IN NEWLY DIAGNOSED POLYCYTHEMIA VERA PATIENTS

EHA Library, Danijela Lekovic, 4160265

CLINICAL PATHWAYS AND PROGNOSTIC STRATEGIES IN MYELOFIBROSIS: A REAL-WORLD ANALYSIS OF GERMAN PRACTICE

EHA Library, Francisco Henriquez, 4160266

MYMPNVOICE APP: REMOTE LONGITUDINAL MONITORING OF PATIENT REPORTED OUTCOMES AND BIOMETRICS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Patrick Harrington, 4160269

REAL-WORLD OUTCOMES OF PATIENT WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA TREATED WITH BRENTUXIMAB-VEDOTIN IN ASSOCIATION WITH BENDAMUSTINE: THE FRENCH LYSA EXPERIENCE

EHA Library, Gaétan Basile, 4160270

EVALUATION OF LONG-TERM OUTCOMES IN ADVANCED STAGE CLASSIC HODGKIN LYMPHOMA TREATED WITH ABVD USING A PET-GUIDED STRATEGY

EHA Library, Jowon Laura Kim, 4160271

REAL WORLD PATIENT CHARACTERISTICS, TREATMENT PATTERNS AND OUTCOMES FOR CHINESE PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA

EHA Library, Kaiyang Ding, 4160279

ADULT LYMPHOMA-ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: CLINICAL FEATURES, DIAGNOSTIC CHALLENGES, AND TREATMENT OUTCOMES—A 24-YEAR SINGLE-CENTER RETROSPECTIVE ANALYSIS

EHA Library, Humberto Nieves-Jiménez, 4160280

SURVIVAL TRENDS IN HODGKIN LYMPHOMA (HL) FROM 1980 TO 2020: EXPERIENCE FROM A REFERRAL CENTER

EHA Library, Theodoros Vassilakopoulos, 4160281

EVOLUTION OF TREATMENT PARADIGMS AND SURVIVAL OUTCOMES IN HODGKIN'S LYMPHOMA: A 20-YEARS' RETROSPECTIVE ANALYSIS OF 804 PATIENTS FROM A NATIONAL MEDICAL CENTER IN CHINA

EHA Library, Wenyan Yu, 4160282

EVALUATION OF GONADAL FUNCTION IN FEMALE PATIENTS WITH HODGKIN LYMPHOMA (HL) AND PRIMARY MEDIASTINAL B-CELL LYMPHOMA (PMBCL) UNDERGOING CHEMOTHERAPY

EHA Library, Angeliki Georgopoulou, 4160283

EFFICACY AND SAFETY OF FIRST-LINE IBRUTINIB PLUS VENETOCLAX IN PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO WERE OLDER OR HAD TP53 MUTATIONS IN THE SYMPATICO STUDY

EHA Library, Gottfried von Keudell, 4160284

EFFICACY OF POLA-R-CHP IN PREVIOUSLY UNTREATED CD5-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Junqing Xu, 4160386

CRP-ALBUMIN-LYMPHOCYTE (CALLY) INDEX: A PROMISSING PROGNOSTIC TOOL IN DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Zorica Cvetković, 4160387

HYPER-FRACTIONATED RADIOTHERAPY BRIDGING CAR-T FOR AGGRESSIVE B-CELL CNS LYMPHOMA

EHA Library, Jing Ruan, 4160388

COMPARISON OF WHOLE BRAIN RADIOTHERAPY (RT) VERSUS AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL): A REAL WORLD PROPENSITY SCORE (PS) MATCHING ANALYSIS

EHA Library, Jiao Jie Cherie Tan, 4160389

THE ABSOLUTE MONOCYTE AND LYMPHOCYTE PROGNOSTIC MODEL IDENTIFIES HIGH-RISK PATIENTS AND PREDICTS OUTCOMES IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

EHA Library, Wenhui Guo, 4160391

SINGLE-CELL RNA SEQUENCING OF PERIPHERAL BLOOD REVEALS IMMUNE CELL SIGNATURES IN EBV-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, QingQing Luo, 4160394

TARGETING MYH9-PRC1 AXIS EXERTS ANTI-TUMOR EFFECTS IN DIFFUSE LARGE B-CELL LYMPHOMA BY REGULATING PINK1/PARKIN-MEDIATED MITOPHAGY

EHA Library, Shunfeng Hu, 4160398

CHARACTERIZING TUMOR MICROENVIRONMENT HETEROGENEITY IN EBV+NTNKL VS ENKTCL USING SPATIAL TRANSCRIPTOMICS AND MIF

EHA Library, Siyu Qian, 4160400

NOVEL ROLE OF CHIDAMIDE IN TAM REPROGRAMMING AND IMMUNOTHERAPY ENHANCEMENT THROUGH RNA SPLICING

EHA Library, Caiqin Wang, 4160404

LONGITUDINAL TARGETED CTDNA ANALYSIS TO ASSESS CD20 AND BAFF MUTATIONS IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FL OR DLBCL PROGRESSING ON ODRONEXTAMAB TREATMENT IN THE ELM-2 STUDY

EHA Library, Stefano Luminari, 4160405

ALTITUDE-1: REAL-WORLD TREATMENT PATTERNS ASSOCIATED WITH ELRANATAMAB AMONG PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Rahul Banerjee, 4160205

FUNCTIONAL GERIATRIC ASSESSMENT TESTS PREDICT TOXICITY RATES IN FUNCTIONAL HIGH RISK MYELOMA PATIENTS TREATED WITH DARATUMUMAB, CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN A PROSPECTIVE CLINICAL TRIAL

EHA Library, Yael Cohen, 4160206

TRIAL IN PROGRESS: QUINTESSENTIAL - A PHASE 2 STUDY OF ARLOCABTAGENE AUTOLEUCEL (ARLO-CEL) IN TRIPLE- AND QUAD-CLASS EXPOSED PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Krina Patel, 4160207

MODELING ADVANCED SYSTEMIC MASTOCYTOSIS: A NOVEL TRANSGENIC MOUSE LINE RECAPITULATES HUMAN DISEASE AND VALIDATES EFFICACY OF AVAPRITINIB

EHA Library, Martina Konantz, 4160209

BCL-XL INHIBITION POTENTIATES INTERFERON-INDUCED APOPTOSIS IN MPN STEM CELLS

EHA Library, Steven Lane, 4160210

3D MODELING OF BONE MARROW FIBROSIS AND ALTERED MEGAKARYOPOIESIS IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Christian Di Buduo, 4160212

DIETARY IRON AFFECTS HAEMATOLOGY AND BONE HEALTH IN A MOUSE MODEL OF POLYCYTHAEMIA VERA

EHA Library, Cavan Bennett, 4160220

IMMUNE-MEGAKARYOCYTES ARE RESPONSIBLE FOR THE PATHOLOGICAL INTERLEUKIN-8 DEPENDENT EMPERIPOLESIS WITH NEUTROPHILS ASSOCIATED WITH MYELOFIBROSIS IN GATA1LOW MICE

EHA Library, Mario Falchi, 4160223

JAK2 V617F VAF AND PRESENCE OF COPY NEUTRAL-LOH AT CHROMOSOME 9P (CHR9P) PREDICTS TRANSFORMATION TO MYELOFIBROSIS (MF) IN PATIENTS WITH POLYCYTHEMIA VERA (PV) ENROLLED IN REVEAL

EHA Library, Stephen Oh, 4160226

THROMBOCYTOPENIA IN MYELOFIBROSIS (MF) IS CHARACTERIZED BY INFLAMMATORY MEGAKARYOCYTES WITH REDUCED G6B EXPRESSION THROMBOCYTOPENIA IN MYELOFIBROSIS IS CHARACTERIZED BY INFLAMMATORY MEGAKARYOCYTES WITH REDUCED G6B EXPRESSION

EHA Library, Lilian Varricchio, 4160229

THE SPATIAL DYSREGULATION OF MICROENVIRONMENT INVOLVING TENASCIN-C EXPRESSING CELLS CAN BE A CLINICALLY APPLICABLE MARKER FOR FIBROSIS PROGRESSION IN THE PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS.

EHA Library, Keiki Nagaharu, 4160230

NEW CRITERIA FOR EVALUATING OUTCOMES OF MYELOFIBROSIS THERAPY: THE EUROPEAN LEUKEMIANET DEMYOS (DESIRABILITY OF MYELOFIBROSIS OUTCOMES)

EHA Library, Monia Marchetti, 4160234

IMPROVEMF UPDATE: PHASE 1/1B TRIAL OF IMETELSTAT (IME)+RUXOLITINIB (RUX) IN PATIENTS WITH INTERMEDIATE (INT)-1, INT-2, OR HIGH-RISK (HR) MYELOFIBROSIS (MF)

EHA Library, John Mascarenhas, 4160237

THE KEY ROLE OF MONOCYTES IN THE EVOLUTION OF MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Wayne-Corentin Lambert, 4160239

DEFINING THE PROGNOSIS FOR ESSENTIAL THROMBOCYTHEMIA: A VALIDATION OF THE AAA+A RISK MODEL AND THE IDENTIFICATION OF A NEW PROGNOSTIC MARKER, THE LYMPHOCYTES-TO-MONOCYTES RATIO

EHA Library, Fabrizio Cavalca, 4160243

GECACITINIB IN JAKI-NAÏVE AND JAKI-EXPOSED MYELOFIBROSIS PATIENTS: IMPROVED TRANSFUSION INDEPENDENCE

EHA Library, Yi Zhang, 4160244

THROMBOSIS RISK AND HORMONE USE IN WOMEN WITH MPN : DATA FROM A CONTEMPORARY COHORT

EHA Library, Ikram-Nour Abda, 4160245

GENE EXPLORATION AND CLINICAL CHARACTERISTICS IN TRIPLE-NEGATIVE ESSENTIAL THROMBOCYTHEMIA VIA WHOLE EXOME SEQUENCING

EHA Library, Siraphop Thammayot, 4160246

IMPACT OF ELN CLINICAL SIGNS AND SYMPTOMS ON OUTCOMES IN POLYCYTHEMIA VERA PATIENTS TREATED WITH HYDROXYUREA OR RUXOLITINIB: A COOPERATIVE STUDY

EHA Library, Francesca Palandri, 4160247

A NEW PROGNOSTIC RISK MODEL IN POLYCYTHEMIA VERA: THE TRIPLE A MODEL

EHA Library, Eda Nuhoğlu Kantarcı, 4160253

GECACITINIB-INDUCED SPLEEN VOLUME REDUCTION (SVR) AND ITS PROGNOSTIC VALUE FOR OVERALL SURVIVAL (OS) IN MYELOFIBROSIS

EHA Library, Yi Zhang, 4160257

OPHTHALMOLOGICAL MANIFESTATIONS OF MYELOFIBROSIS AT THE ONSET AND DURING THERAPY

EHA Library, Olga Vinogradova, 4160258

A REAL-WORD STUDY ON THE EFFICACY AND SAFETY OF SELINEXOR PLUS RUXOLITINIB REGIMEN IN RUXOLITINIB-RESISTANT MYELOFIBROSIS

EHA Library, Na Xu, 4160261

A PHASE 1B/2 STUDY OF DISC-0974, AN ANTI-HEMOJUVELIN ANTIBODY, IN PATIENTS WITH MYELOFIBROSIS AND ANEMIA

EHA Library, Sima Bhatt, 4160263

ASSESSMENT OF RISK FACTORS AND ANTICOAGULATION STRATEGY IN MYELOPROLIFERATIVE NEOPLASM-ASSOCIATED SPLANCHNIC VEIN THROMBOSIS (MPN-SVT): SINGLE-CENTRE, LONG-TERM, REAL-WORLD DATA.

EHA Library, Elena Torre, 4160267

AN OPEN-LABEL CLINICAL TRIAL OF RVU120 AS MONOTHERAPY AND IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK, PRIMARY OR SECONDARY MYELOFIBROSIS (POTAMI-61).

EHA Library, Rostislav Kuklík, 4160268

TREATMENT EFFICACY FOR ADVANCED-STAGE CLASSIC HODGKIN LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS

EHA Library, Rong Tao, 4160272

PROGNOSTIC VALUE OF PET/CT BEFORE AUTOLOGOUS STEM-CELL TRANSPLANTATION IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA

EHA Library, Justin Ferdinandus, 4160273

FIVE-YEAR EXPERIENCE WITH PD-1 INHIBITOR COMBINATION REGIMENS IN REFRACTORY CLASSIC HODGKIN LYMPHOMA AFTER FAILURE OF IMMUNE CHECKPOINT INHIBITOR MONOTHERAPY

EHA Library, Julia Zhuravleva, 4160274

PET-ADAPTED THERAPY AFTER THREE CYCLES OF ABVD FOR ALL STAGES OF HODGKIN LYMPHOMA: LONG-TERM FOLLOW-UP OF THE GATLA LH-05 TRIAL

EHA Library, Astrid Pavlovsky, 4160275

CONSOLIDATION TREATMENT WITH BRENTUXIMAB VEDOTIN AFTER ALLOGENEIC STEM-CELL TRANSPLANTATION FOR RELAPSED HODGKIN LYMPHOMA: ANALYSIS OF THE GHSG PHASE 2 BV-ALLO TRIAL

EHA Library, Christof Scheid, 4160276

CHARACTERISTICS AND PREDICTORS OF EARLY DEATHS IN CLASSICAL HODGKIN LYMPHOMA

EHA Library, Cong Sun, 4160277

RESPONSE ADAPTED THERAPY OF PEDIATRIC CLASSIC HODGKIN LYMPHOMA ACCORDING TO MODIFIED EURO-NET PROTOCOL-SINGLE CENTER EXPERIENCE

EHA Library, Hani Abdel Rahman Sayed, 4160278

A NOVEL PROGNOSTIC MODEL INCORPORATING SERUM ß2-MICROGLOBULIN IN PRIMARY CNS LYMPHOMA

EHA Library, Yeokyeong Shin, 4160385

POLA-R-CHP PERFORMED WELL IN POLARIX TRIAL-INELIGIBLE AND LOW RISK (IPI 0-1) PATIENTS WITH PREVIOUSLY UNTREATED DLBCL: A PROSPECTIVE OBSERVATIONAL STUDY

EHA Library, Yuhong Ren, 4160390

REAL WORLD DATA ON USE OF RITUXIMAB IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) IN HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTED PATIENTS.

EHA Library, Lay Khandwala, 4160392

SINGLE-CELL ATLAS OF PRIMARY CNS LYMPHOMA REVEALS AN IMMUNE-RICH TUMOUR MICROENVIRONMENT MODULATED BY ENDOTHELIAL CELLS AND CANCER-ASSOCIATED FIBROBLASTS

EHA Library, Keir Pickard, 4160393

STROMAL CELL DIVERSITY IN ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA THROUGH SPATIAL TRANSCRIPTOME ANALYSIS AT SINGLE CELL RESOLUTION

EHA Library, Yuki Shimizu, 4160395

CD73 MODULATES IMMUNE ESCAPE VIA TRYPTOPHAN METABOLIC REPROGRAMMING IN DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Yingfang Feng, 4160396

CLINICAL IMPACT OF UNTARGETED BASELINE PLASMA METABOLOMICS IN NEWLY DIAGNOSED DIFFUSE LARGE B CELL LYMPHOMA

EHA Library, Riccardo Dondolin, 4160397

MULTI-OMICS ARCHITECTURE OF PLASMABLASTIC LYMPHOMA: EBV-MEDIATED AND GENOTYPE-SPECIFIC EFFECTS ON THE TUMOR MICROENVIRONMENT AND THERAPEUTIC VULNERABILITIES

EHA Library, Niklas Gebauer, 4160399

IDENTIFICATION OF PLASMA PROTEINS ASSOCIATED WITH DIFFUSE LARGE B-CELL LYMPHOMA: A UK BIOBANK-BASED PROSPECTIVE STUDY

EHA Library, QingQing Luo, 4160401

WHOLE-GENOME SEQUENCING REVEALS THREE FOLLICULAR LYMPHOMA SUBTYPES WITH DISTINCT CELL-OF-ORIGIN AND PATIENT OUTCOMES

EHA Library, Weicheng Ren, 4160402

INACTIVATION OF CYLD INDUCES THE EXPANSION OF SPLENIC MARGINAL ZONE PRECURSOR B CELLS

EHA Library, Athanasios Pseftogkas, 4160403